Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Expanded Access IND Administration of HBOC-201 in Patients With Severe Acute Anemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03633604
Expanded Access Status : Available
First Posted : August 16, 2018
Last Update Posted : May 7, 2021
Sponsor:
Collaborator:
HbO2 Therapeutics LLC
Information provided by (Responsible Party):
Jonathan H. Waters, University of Pittsburgh

Study Description
Go to 
Top of Page Study Description Study Design Interventions Eligibility Criteria Contacts and Locations More Information
Brief Summary:

HBOC-201 provides an oxygen treatment bridge and can be used to eliminate, delay, or reduce the need for red blood cell transfusions in anemic patients

This is an expanded access IND protocol, and will provide treatment with HBOC-201 to severely anemic adults for whom blood is not an option


Condition or disease Intervention/treatment
Anemia Severe Biological: HBOC-201

Detailed Description:

HBOC 201 [hemoglobin glutamer - 250 (bovine)] is an investigational agent, manufactured by Hemoglobin Oxygen Therapeutics LLC (HbO2 Therapeutics), located in Souderton, PA. HBOC-201, has been previously studied17-20 as an alternative to blood transfusions in severely anemic patients needing a way to enhance tissue oxygenation. HBOC-201 is purified, cross-linked and polymerized acellular bovine hemoglobin (Hb) in a modified lactated Ringer's solution, and does not require blood compatibility.

HBOC-201 is an oxygen carrying fluid that increases plasma and total hemoglobin concentration. HBOC-201 has a right-shifted oxygen binding equilibrium curve with a P50 of 40 ± 6 mmHg compared to 27 mmHg for corpuscular hemoglobin. When fully saturated, HBOC-201 binds approximately 1.39 mL of oxygen per gram hemoglobin and, therefore, has the same oxygen carrying capacity as whole blood having the same hemoglobin concentration. To the extent that HBOC-201 administration increases the total hemoglobin concentration in circulation, HBOC-201 is capable of increasing convective oxygen delivery (DO2), defined as the product of blood oxygen content (ml O2/ml blood) and volumetric blood flow (ml blood/min.) At concentrations corresponding to at least 10% of the total hemoglobin concentration, HBOC-201 also facilitates diffusive oxygen delivery, primarily by shortening diffusion distances between RBCs and between RBCs and the endothelium. The higher P50 of HBOC-201 compared to that of cellular hemoglobin further facilitates diffusion of oxygen from RBCs to tissues through increased oxygen off-loading.

HBOC-201 provides an oxygen treatment bridge and can be used to eliminate, delay, or reduce the need for red blood cell transfusions in anemic patients

This is an expanded access IND protocol, and will provide treatment with HBOC-201 to severely anemic adults for whom blood is not an option.

Study Design
Go to 
Top of Page Study Description Study Design Interventions Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Expanded Access
Expanded Access Type : Intermediate-size Population
Official Title: An Expanded IND Access Investigation of HBOC-201 Infusion in Patients With Severe Acute Anemia Who Are Unable to Receive Red Blood Cell Transfusion

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Anemia

Interventions
Go to 
Top of Page Study Description Study Design Interventions Eligibility Criteria Contacts and Locations More Information

Intervention Details:
  • Biological: HBOC-201
    Intravenous administration of a hemoglobin based oxygen carrier (HBOC) in patients with life-threatening anemia, for whom allogeneic blood transfusion is not an option.
    Other Names:
    • Hemopure
    • hemoglobin glutamer - 250 (bovine)
Eligibility Criteria
Go to 
Top of Page Study Description Study Design Interventions Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

  1. Patients ≥ 18 years of age
  2. Critically ill patients with hemoglobin ≤ 6 g/dL (or 7-8 g/dL with significant active bleeding), and physiologic evidence of critical ischemia, for example: elevated troponins, altered mental status, acute renal failure, lactic acidosis or evidence of central nervous system acute deficits
  3. Patients or their Legally Authorized Representative who are able and willing to provide informed consent

  4. Blood is not an option due to:

    • refusal of transfusion
    • lack of compatible red blood cells

Exclusion Criteria:

  1. Patients with known hypersensitivity or allergy to beef products
  2. Patients with pre-existing uncontrolled hypertension, heart failure, renal failure (caution should be exercised if renal insufficiency is present), circulatory hypervolemia or systemic mastocytosis*
  3. Patients who are eligible for blood transfusions
  4. Patients who are > 80 years old*

  5. Pregnant or lactating women

    • on a case by case and quality of life determination
Contacts and Locations
Go to 
Top of Page Study Description Study Design Interventions Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03633604


Contacts
Layout table for location contacts
Contact: Amy Monroe 412-609-6161 monroeal@upmc.edu
Contact: Stephanie Nam 412-722-5477 nams@upmc.edu

Locations
Layout table for location information
United States, Pennsylvania
University of Pittsburgh Medical Center Available
Pittsburgh, Pennsylvania, United States, 15213
Contact: Amy Monroe    412-609-6161    monroeal@upmc.edu   
Principal Investigator: Jonathan H Waters, MD         
Sub-Investigator: Darrell Triulzi, MD         
Sponsors and Collaborators
Jonathan H. Waters
HbO2 Therapeutics LLC
More Information
Go to 
Top of Page Study Description Study Design Interventions Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Jonathan H. Waters, Professor, University of Pittsburgh
ClinicalTrials.gov Identifier: NCT03633604    
Other Study ID Numbers: PRO18050626
First Posted: August 16, 2018    Key Record Dates
Last Update Posted: May 7, 2021
Last Verified: May 2021
Keywords provided by Jonathan H. Waters, University of Pittsburgh:
Hematologic Diseases
Blood Substitutes
Additional relevant MeSH terms:
Layout table for MeSH terms
Anemia
Hematologic Diseases
HBOC 201
Blood Substitutes